Explore

Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Veradermics Reports Q1 2026 Financial Results and Clinical Progress in Hair Loss Treatment

Veradermics Reports Q1 2026 Financial Results and Clinical Progress in Hair Loss Treatment

Veradermics Reports Q1 2026 Financial Results and Clinical Progress in Hair Loss Treatment
Trendline Trendline
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call

Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call
Trendline Trendline
Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026

Verastem Oncology to Present at Key Investor Conferences in May 2026
Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Iambic Announces Participation in Major Healthcare and Technology Investor Conferences

Iambic Announces Participation in Major Healthcare and Technology Investor Conferences

Iambic Announces Participation in Major Healthcare and Technology Investor Conferences
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments

Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Developments
Trendline Trendline
Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases
Trendline Trendline
Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments

Atossa Therapeutics Reports Q1 2026 Financial Results and Strategic Developments
Trendline Trendline
Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges

Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges

Soligenix Reports First Quarter 2026 Financial Results Amid Clinical Trial Challenges